| 2.325 0.155 (7.14%) | 04-13 15:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.81 | 1-year : | 3.13 |
| Resists | First : | 2.4 | Second : | 2.68 |
| Pivot price | 2.19 |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.27  |
MA(20) : | 2.2 |
| MA(100) : | 2.11 |
MA(250) : | 2.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 67.3 | D(3) : | 69.2 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 2.8 | Low : | 1.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NKTX ] has closed below upper band by 24.1%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.33 - 2.35 | 2.35 - 2.36 |
| Low: | 2.1 - 2.12 | 2.12 - 2.13 |
| Close: | 2.15 - 2.17 | 2.17 - 2.19 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sat, 11 Apr 2026
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Thu, 09 Apr 2026
Nkarta leaders to discuss autoimmune cell therapy at Needham event - Stock Titan
Thu, 09 Apr 2026
Nkarta to Participate in Needham Virtual Healthcare Conference - Sahm
Wed, 25 Mar 2026
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41) - TradingView — Track All Markets
Wed, 25 Mar 2026
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights - GlobeNewswire
Fri, 23 Jan 2026
Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 78 (%) |
| Shares Short | 5,520 (K) |
| Shares Short P.Month | 6,470 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16 % |
| Return on Equity (ttm) | -28.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -89 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -1.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|